Eli Lilly rolls out LillyDirect to ship Mounjaro directly to Australian patients, sparking pharmacist concerns

Eli Lilly announced a new service called LillyDirect that will deliver its diabetes drug Mounjaro straight to the homes of patients in Australia, bypassing the traditional pharmacy channel.

The model operates as a direct‑to‑consumer offering: patients receive prescriptions from their doctors, and the medication is shipped from Lilly’s distribution network to their doorsteps, eliminating the need to pick up the drug at a local pharmacy.

Local doctors and pharmacists have expressed disappointment, saying the approach removes a key point of care and could complicate monitoring of patient adherence and safety.

Industry observers note that the move reflects a broader trend of pharmaceutical companies seeking more control over drug distribution, though its impact on the Australian healthcare system remains to be seen.